Michael Smylie

36.5k citations
92 papers · 9.1k indexed · 3 hit papers · h-index 30
Topics
CAR-T cell therapy research (43 papers)Cancer Immunotherapy and Biomarkers (41 papers)Melanoma and MAPK Pathways (24 papers)
Partner nations
CanadaUnited StatesItaly

In The Last Decade

Michael Smylie

88 papers receiving 8.9k citations

Hit Papers

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer200520262012201920052018200910002.0k3.0k4.0k

Peers

Michael Smylie
Comparison fields: 5 of 112
  • Oncology 7.2k
  • Pulmonary and Respiratory Medicine 4.4k
  • Molecular Biology 2.4k
  • Immunology 1.6k
  • Cancer Research 1.0k
Replace Daniil Stroyakovskiy with:
Daniil Stroyakovskiy Russia
Emiliano Calvo Spain
Jean‐Pierre Delord France
Jamie E. Chaft United States
Petri Bono Finland
Daniel Castellano Spain
Laura Q.M. Chow United States
Jonathan E. Rosenberg United States
Theodore F. Logan United States
Scott Gettinger United States
Michael Smylie relative to Daniil Stroyakovskiy Russia Daniil Stroyakovskiy's profile →
Citations per field
00.5×1.6×
Daniil Stroyakovskiy · 1×
Citations per year

Countries citing papers authored by Michael Smylie

Since Specialization
Citations

This map shows the geographic impact of Michael Smylie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Smylie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Smylie more than expected).

Fields of papers citing papers by Michael Smylie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Smylie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Smylie. The network helps show where Michael Smylie may publish in the future.

Co-authorship network of co-authors of Michael Smylie

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Smylie. A scholar is included among the top collaborators of Michael Smylie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Smylie. Michael Smylie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 13
4 123
5 47
6
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialbreakdown →
1009
7 8
8 3
9 17
10 80
11 95
12 13
13
EFFECT OF DOSE ON EFFICACY AND SAFETY IN IPILIMUMAB-TREATED PATIENTS WITH ADVANCED MELANOMA - RESULTS FROM A PHASE II, RANDOMIZED, DOSE-RANGING STUDY
6
14 13
15 36
16 11
17 89
18 6
19 202
20 192

About Michael Smylie

Michael Smylie is a scholar working on Oncology, Immunology and Cancer Research, having authored 92 papers that have together received 9.1k indexed citations. Recurring topics across this work include CAR-T cell therapy research (43 papers), Cancer Immunotherapy and Biomarkers (41 papers) and Melanoma and MAPK Pathways (24 papers). The work is most often cited by research in Oncology (7.2k citations), Pulmonary and Respiratory Medicine (4.4k citations) and Immunology (1.6k citations). Michael Smylie has collaborated with scholars based in Canada, United States and Italy. Frequent co-authors include Frances A. Shepherd, Lesley Seymour, Vera Hirsh, Andrea Bezjak, B. Findlay, P. Santabárbara, Mircea Dediu, D. Johnston, Daniel de Castro and Dongsheng Tu. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026